Mark Hickinson

Title: Mark Hickinson: Innovator in Antibody Development

Introduction

Mark Hickinson is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the ErbB2 protein. With a total of 2 patents to his name, his work has implications for both diagnosis and treatment in medical applications.

Latest Patents

Hickinson's latest patents focus on antibodies directed to ERBB2. The inventions include human antibodies and antigen-binding portions that specifically bind to ErbB2, with a preference for human ErbB2. These antibodies are designed to inhibit ErbB2 and can be chimeric, bispecific, derivatized, or single-chain antibodies. The patents also cover isolated heavy and light chain immunoglobulins derived from human anti-ErbB2 antibodies, along with nucleic acid molecules encoding these immunoglobulins. Furthermore, the inventions provide methods for using these antibodies in diagnosis and treatment, as well as gene therapy methods utilizing nucleic acid molecules that encode the immunoglobulin molecules. The patents also extend to transgenic animals or plants that incorporate these nucleic acid molecules.

Career Highlights

Mark Hickinson is currently associated with Medimmune Limited, where he continues to advance his research in antibody development. His work has been instrumental in pushing the boundaries of therapeutic options available for conditions related to ErbB2.

Collaborations

Hickinson has collaborated with notable colleagues such as Susan Ann Cartlidge and Jianying Dong, contributing to a dynamic research environment that fosters innovation.

Conclusion

Mark Hickinson's contributions to the field of biotechnology, particularly in the development of antibodies targeting ErbB2, highlight his role as a significant inventor. His work not only advances scientific understanding but also has the potential to improve therapeutic strategies in medicine.